Dataset Information


Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.

ABSTRACT: BACKGROUND:Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegylated G-CSF (Neulasta®, Amgen) with sustained release properties. This is a randomized, comparative, double-blind, multicenter study to evaluate efficacy and safety of RGB-02 in breast cancer patients receiving cytotoxic regimen. METHODS:Two hundred thirty-nine women presenting with breast cancer were randomized to RGB-02 (n?=?121) and the reference product (n?=?118). All patients received up to 6?cycles of docetaxel/doxorubicin chemotherapy combination and a once-per-cycle injection of a fixed 6?mg dose of pegfilgrastim. Primary endpoint was the duration of severe neutropenia (ANC?


PROVIDER: S-EPMC6364429 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6469669 | BioStudies
2016-01-01 | S-EPMC5705792 | BioStudies
2018-01-01 | S-EPMC6127997 | BioStudies
2016-01-01 | S-EPMC4943394 | BioStudies
2020-01-01 | S-EPMC7467414 | BioStudies
1000-01-01 | S-EPMC4819939 | BioStudies
2018-01-01 | S-EPMC6256001 | BioStudies
2020-01-01 | S-EPMC7183238 | BioStudies
1000-01-01 | S-EPMC6094503 | BioStudies
2016-01-01 | S-EPMC4766213 | BioStudies